Sanofi, the renowned global biopharmaceutical company, is accelerating the separation of its
$20 billion consumer health unit and is in the process of receiving initial bids. The company showcased some of its innovative approaches at the VivaTech event. Its collaboration with
Astra-Sanofi has given a green light to a new vaccine for infants. Significant investment inflows were also evident with the $40M funding of
Vigil Neuroscience and a whopping $372M series D funding for
Formation, an AI-focused firm who collaborates on
AI-driven drug development. Additional partnerships were announced with Biovac and EuBiologics to enhance Africa's supply of vaccines, as well as Novavax in a $1.2 billion deal. Despite ongoing restructuring and generic competition which have affected the firm’s profit, Sanofi has made a $80M gamble on Fulcrum's muscular dystrophy drug and bought US drugs project
INBRX-101 for roughly $2.2 billion. The company has committed €1 billion to French production sites and enlisted the banks' help to create a pitch for its $20 billion OTC spinoff. The firm also plans to revamp its US vaccine operations and announced a $100 million settlement for Zantac cancer lawsuits.
Sanofi News Analytics from Tue, 19 Sep 2023 07:00:00 GMT to Sun, 30 Jun 2024 17:56:00 GMT -
Rating 8
- Innovation 8
- Information 9
- Rumor -2
